Dimensional Fund Advisors LP Has $11.38 Million Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Dimensional Fund Advisors LP raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 17.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,013,807 shares of the biopharmaceutical company's stock after buying an additional 292,172 shares during the period. Dimensional Fund Advisors LP owned approximately 3.45% of Vanda Pharmaceuticals worth $11,379,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of VNDA. Profit Investment Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 159.3% in the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company's stock valued at $3,228,000 after acquiring an additional 351,000 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter valued at $1,158,000. Monaco Asset Management SAM acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at $1,090,000. GSA Capital Partners LLP boosted its stake in Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company's stock valued at $2,396,000 after buying an additional 161,737 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in Vanda Pharmaceuticals by 39.6% during the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company's stock worth $2,132,000 after acquiring an additional 147,066 shares during the period. Institutional investors and hedge funds own 88.14% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Monday, September 30th. They set a "hold" rating for the company. Cantor Fitzgerald upped their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an "overweight" rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA traded down $0.13 during midday trading on Monday, reaching $4.50. The company had a trading volume of 126,332 shares, compared to its average volume of 1,381,725. The company has a fifty day simple moving average of $5.12 and a two-hundred day simple moving average of $5.19. The firm has a market cap of $262.31 million, a price-to-earnings ratio of -57.88 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 1-year low of $3.30 and a 1-year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The firm had revenue of $50.47 million during the quarter. Analysts expect that Vanda Pharmaceuticals Inc. will post -0.49 EPS for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.